Acadia Pharmaceuticals (ACAD) Other Accumulated Expenses (2011 - 2026)

Acadia Pharmaceuticals' Other Accumulated Expenses history runs 16 years deep, the most recent figure standing at $16.1 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 72.49% year-over-year to $16.1 million in Q1 2026; TTM through Mar 2026 was $16.1 million, a 72.49% increase from a year earlier, with the FY2025 full-year figure at $5.9 million, up 73.78% from the prior year.
• Other Accumulated Expenses rose to $16.1 million in Q1 2026 per ACAD's latest filing, from $5.9 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $16.1 million in Q1 2026 and bottomed at $986000.0 in Q2 2022.
• The 5-year median for Other Accumulated Expenses is $8.9 million (2024), against an average of $7.8 million.
• Across the five-year window, Other Accumulated Expenses soared 777.84% in 2023 and plunged 69.31% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $2.7 million in 2022, then jumped by 307.53% to $11.0 million in 2023, then sank by 69.31% to $3.4 million in 2024, then soared by 73.78% to $5.9 million in 2025, then jumped by 173.92% to $16.1 million in 2026.
• Per Business Quant, the three latest ACAD Other Accumulated Expenses figures stand at $16.1 million (Q1 2026), $5.9 million (Q4 2025), and $5.0 million (Q3 2025).